Marion Provost

• A global pharmaceutical group in a case before the French Competition Authority and the Paris court of appeal relating to an alleged abuse of collective dominance concerning the “off label use” of its drug in the ophthalmic field.
• A global biopharmaceutical group in investigations led by the European Commission and the Swiss Competition Commission for potential involvement of a subsidiary in a worldwide cartel.
• A global animal health company in a complaint before the European Commission leading to the investigation of a potential “killer acquisition”.
• A major pharmaceutical firm on the lifecycle management of several drugs in one of their franchises, in the context of biosimilars’ entry on the market, with a focus on product hopping and commercial policies issues.
• A global support services company in the assessment of the opportunity to apply for leniency before the French Competition Authority (internal audit) and in the assessment of its compliance with certain rules of the French Commercial Code concerning price transparency and unfair commercial practices.
• A leading consumer packaged food and beverage company in a merger control filing before the European Commission.
• An international bank in the context of a major EU investigation concerning potential manipulation of the Euribor rate.
• A manufacturer of electronic devices in the context of an investigation by the French Competition Authority concerning a potential abuse of dominant position and anticompetitive agreements with its distributors.
• A sugar manufacturer during a dawn-raid conducted by the European Commission.
• Various clients regarding the conduct of internal audits.
• A wholesale distributor of automotive spare parts in a merger control filing before the European Commission.
• A wholesale distributor of automotive spare parts in a merger control filing before the French Competition Authority regarding the acquisition of sole control over a retailer of automotive spare parts for light vehicles.
• A manufacturer and distributor of frozen food in a merger control filing before the French Competition Authority regarding the acquisition of sole control over a competitor.
• A French insurance company on merger control issues arising from the acquisition of the French insurance and bank activities of a UK financial institution, which requires clearance by the French Competition Authority.

Includes matters handled at Dechert or prior to joining the firm.

• Actions en réparation des pratiques anticoncurrentielles/ Private Enforcement — Cour d’Appel de Paris (April 18, 2023)
• Sommet du Droit : Private enforcement, les entreprises face à l’effet ricochet — Conférence Décideurs (January 25, 2023)
• Actions en réparation des pratiques anticoncurrentielles, State of private actions in the EU: the point of view of professionals — Conférence Concurrences, Paris (March 30, 2022)
  
• Life Sciences Academy, Enquêtes/Investigations — Paris, France (February 15, 2022)
  
• EU Pharmaceutical Law Forum — Virtual conference (May 17-20, 2021)
• Life Sciences Academy — Paris, France (October 2, 2018)
• Transactions en droit de la concurrence — Business & Legal Forum, Paris (October 12, 2017)

• Pharmaceutical Antitrust Book — Concurrences (November 30, 2023) 
• Accords de report d'entrée : la sanction de 60,5 millions d'euros pour Teva et Cephalon confirmée — Blog de l’Usine Nouvelle (November 1, 2023)
• The Instrumentalization of Intellectual Property Rights for Anticompetitive Purposes in the Pharmaceutical Industry A New Territory for Competition Authorities in Europe — Concurrences (September 4, 2023)
• France: Pedagogical approach of courts and increased FCA enforcement contribute to rise in private antitrust litigation — Global Competition Review (July 30, 2023)
• Impactful decisions exemplify FCA and Supreme Administrative Court's evolving merger control — Global Competition Review (June 30, 2023)
• Vers un élargissement du champ du contrôle des autorités de concurrence européennes dans les concentrations d’entreprises — Blog de l’Usine Nouvelle (April 14, 2023)
• Dominance in the pharmaceutical sector: An Overview of EU and national case law — Concurrences (March 2, 2023)
• Pourquoi la Commission européenne a interdit l'opération Illumina/Grail — Blog de l’Usine Nouvelle (October 21, 2022)
• Le secteur de la santé sous la présidence d'Emmanuel Macron : rétrospectives et perspectives — Concurrences (March 31, 2022)
• Affaire Plavix : revirement dans le volet « private enforcement » — Blog L’Usine Nouvelle (March 26, 2022)
• Principe d’effectivité, notion d’unité économique et responsabilité civile : de quelques enseignements de l’affaire Sumal — Revue Concurrences (February 24, 2022)
  
• Global Competition Review Cases and Precedents: Vertical Restraints – Global Competition Review (January 3, 2022)
• Cartel Regulation — Getting The Deal Through (January 3, 2022)
• Dominance in the Pharmaceutical Sector: An Overview of EU and National Case Law — e-Competitions Review (December 23, 2021)
• Sanction de Roche et Novartis pour discours « trompeur » sur l’utilisation d’Avastin dans la DMLA : quand l’Autorité de la concurrence s’érige en censeur des communications entre les laboratoires et les autorités de santé — Blog Usine Nouvelle (January 25, 2021)
• European Commission repurposes powers to capture deals not meeting filing thresholds in the EU — (March 31, 2021)
• Dawn raids at French supermarkets partially annulled by EU court — (October 21, 2020)
  
• Dominance in the Pharmaceutical Sector: An Overview of EU and National Case Law — e-Competitions Review (November 21, 2019)
• Settlement before the Competition Authority: beyond appearances, do companies really stand to gain? — Revue Lamy Droit des Affaires (May 24, 2019)